Generic drug maker Juno Pharmaceuticals and US-based Millennium Pharmaceuticals have reached an in-principle settlement in their trans-Pacific dispute over two patents covering breakthrough anti-cancer medication Velcade.
A judge has refused an application by generic drug maker Juno Pharmacueticals to withdraw an admission in a battle with Millennium Pharmaceuticals over its cheap version of breakthrough cancer drug Velcade, denying Juno a potential defence to allegations of patent infringement.
Juno Pharmaceuticals has resolved its appeal of an IP Australia ruling that allowed Seattle-based Juno Therapeutics to extend protection of its namesake trade mark into Australia.
Generic drug maker Dr Reddy’s Laboratories has reached a settlement with US-based Millennium Pharmaceuticals, agreeing to be restrained from selling a cheap version of cancer drug Velcade in Australia.
US-based Millennium Pharmaceuticals has secured a temporary injunction that bans generic drug maker Juno Pharmaceuticals from importing or selling its cheap version of breakthrough cancer drug Velcade in Australia.
An urgent injunction sought by US-based Millennium Pharmaceuticals to block generic drug maker Dr Reddy’s Laboratories from launching a cheap version of the breakthrough cancer drug Velcade has been panned as unnecessary.
Two patent infringement lawsuits have been launched over attempts to sell generic versions of breakthrough cancer drug Velcade in Australia, after a US court last year struck down attempts to invalidate a patent for the drug.